**Author’s response to reviews**

**Title:** Effect of low dose naloxone on the immune system function of a patient undergoing videoassisted thoracoscopic resection of lung cancer with sufentanil controlled analgesia — a randomized controlled trial.

**Authors:**

Lin Yun (linyun992@126.com)

Miao Zhuang (18098876195@163.com)

Wu Yue (wuyue0903@126.com)

Ge Fangfang (1195739917@qq.com)

Wen Qingping (601460646@qq.com)

**Version: 2 Date: 24 Nov 2019**

**Author’s response to reviews:**

Dear editors,

Thank you for arranging a timely review for our manuscript. We have carefully evaluated the reviewers’ critical comments and thoughtful suggestions, responded to these suggestions point-by-point, and revised the manuscript accordingly. All changes made to the text are in red so that they can be easily identified. With regard to the reviewers’ comments and suggestions, we would like to reply as follows:

Jose Navas, MD (Reviewer 1):

Q: I find really hard to believe that ALL your patients were ASA 2. I suggest either remove the ASA status from the paper (since it will not change the overall picture) or revise the ASA classification of these patients when they went to the OR.

A: We thank the reviewer to raise this important issue. Most of the patients have surgery in our hospital because pulmonary nodules were found through physical examination. There were no obvious symptoms or signs before the examinations. We did not include patients in serious conditions in the test in order not to affect the results. We have made some adjustments after careful check on patient information. TABLE 1 has been modified (TABLE 1, Page 20)